Single-Use Boosts Fill/Finish in Commercial Biomanufacturing

Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.
Jun 15, 2018
Volume 2018 eBook, Issue 2, pg 13–17

The increasing number of biologic drugs in development is driving the need for more efficient and cost-effective manufacturing technologies, including in single-use technologies for final fill/finish. Single-use technologies have become increasingly prevalent in fill/finish as a result of industry demand.

BioPharm Internationalspoke to BJ Hull, vice-president and general manager (Camden), Emergent BioSolutions; Sara Bell, senior marketing manager, Single-use Solutions, MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany; and Claus Feussner, PhD, senior vice-president Vetter Development Service, Vetter Pharma-Fertigung, on the adoption, benefits, and challenges of single-use systems in final fill/finish manufacturing.

Read this article in BioPharm International's Single-Use Systems 2018 eBook.

Article Details

BioPharm International
eBook: BioPharm International Single-Use Systems
Vol. 31
June 2018
Pages: 13–17

Citation

When referring to this article, please cite it as F. Mirasol, “Single-Use Boosts Fill/Finish in Commercial Biomanufacturing,” BioPharm International Single-Use Systems eBook (June 2018).

native1_300x100
lorem ipsum